Adaptive Biotechnologies Included in Key Abstracts at ASCO 2022 Supporting the Role of the clonoSEQ® Assay as a Standard for MRD Assessment Technology
June 02 2022 - 3:10PM
Data from Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a
commercial stage biotechnology company that aims to translate the
genetics of the adaptive immune system into clinical products to
diagnose and treat disease, will be included in several abstracts
investigating the impact of MRD in blood cancers at the American
Society of Clinical Oncology (ASCO) Annual Meeting being held June
3-7, in Chicago, Illinois. clonoSEQ® is the first and only U.S.
Food and Drug Administration (FDA)-cleared assay for measuring
minimal residual disease (MRD) in chronic lymphocytic leukemia
(CLL), multiple myeloma (MM) and B-cell acute lymphoblastic
leukemia (B-ALL), and is widely available to clinicians and
patients across the U.S.
MRD is a term used to quantify the number of cancer cells that
may remain in a patient’s body after treatment, even in the absence
of symptoms. These residual cells can be present at very low levels
and require highly sensitive tests like clonoSEQ to identify them.
The presence of even a small number of cells offers prognostic
value to clinicians as they assess how patients respond to
treatment. MRD status may ultimately predict clinical relapse.
“We are excited by the data from both investigator-sponsored and
pharmaceutical-driven presentations utilizing clonoSEQ at ASCO this
year, particularly for novel and highly targeted therapies,” said
Nitin Sood, Chief Commercial Officer, MRD, Adaptive
Biotechnologies. “The burgeoning evidence base supports the
expansion of clonoSEQ as a standard in MRD assessment for lymphoid
cancers and emphasizes the importance of MRD assessment using
clonoSEQ in day-to-day care for patients and physicians.”
Data using clonoSEQ for MRD assessment will be presented across
a range of cancers including multiple myeloma, ALL, CLL and
non-Hodgkin’s lymphoma (NHL) and underscore the significance of
deep responses and identification of patients with better
outcomes.
Key presentations include:
Presentation Type and Number |
Title |
Presentation Timing |
Multiple Myeloma |
Poster Abstract 8028 |
Phase 1b/2 study of ciltacabtagene autoleucel, a BCMA-directed
CAR-T cell therapy, in patients with relapsed/refractory multiple
myeloma (CARTITUDE-1): Two years post-LPI |
Saturday, June 4th8:00 – 11:00 AM CDT |
Poster Abstract 7518 |
Three-year follow-up of outcomes with KTE-X19 in patients with
relapsed/refractory mantle cell lymphoma in ZUMA-2 |
Saturday, June 4th3:00 – 4:30 PM CDT |
Poster Abstract 8014 |
Elranatamab, a BCMA-targeted T-cell redirecting immunotherapy, for
patients with relapsed or refractory multiple myeloma: Updated
results from MagnetisMM-1 |
Saturday, June 4th4:30 – 6:00 PM CDT |
Poster Abstract 8011 |
Daratumumab (DARA) + lenalidomide, bortezomib, and dexamethasone
(RVd) in transplant-eligible newly diagnosed multiple myeloma
(NDMM): A post hoc analysis of sustained minimal residual
disease (MRD) negativity from GRIFFIN |
Saturday, June 4th4:30 – 6:00 PM CDT |
Poster Abstract 8020 |
Biological correlative analyses and updated clinical data of
ciltacabtagene autoleucel (cilta-cel), a BCMA-directed CAR-T cell
therapy, in lenalidomide (len)-refractory patients (pts) with
progressive multiple myeloma (MM) after 1–3 prior lines of therapy
(LOT): CARTITUDE-2, cohort A |
Saturday, June 4th4:30 – 6:00 PM CDT |
Oral Abstract 8003 |
Phase 1 study of CART-ddBCMA in relapsed or refractory multiple
myeloma |
Sunday, June 5th9:00 AM CDT |
Smoldering Multiple Myeloma |
Poster Abstract 8040 |
B-PRISM (Precision Intervention Smoldering Myeloma): A phase II
trial of combination of daratumumab, bortezomib, lenalidomide, and
dexamethasone in high-risk smoldering multiple myeloma |
Saturday, June 4th8:00 – 11:00 AM CDT |
Acute Lymphoblastic Leukemia |
Poster Abstract 10023 |
Minimal residual disease comparison between Ig/TCR PCR versus NGS
assays in children with Philadelphia chromosome-positive acute
lymphoblastic leukemia: A report from the COG AALL1631 study |
Monday, June 6th8:00 – 11:00 AM CDT |
non-Hodgkin Lymphoma |
Poster Abstract 7531 |
Molecular disease monitoring in patients with relapsed/refractory
B-cell non-Hodgkin lymphoma receiving anti-CD19 CAR T-cell
therapy |
Saturday, June 4th8:00 – 11:00 AM CDT |
About the clonoSEQ AssayThe clonoSEQ
Assay is the first and only FDA-cleared assay for MRD in chronic
lymphocytic leukemia (CLL), multiple myeloma (MM) and B-cell acute
lymphoblastic leukemia (ALL). Minimal residual disease (MRD) refers
to the small number of cancer cells that can stay in the body
during and after treatment. clonoSEQ was initially granted De Novo
designation and marketing authorization by the FDA for the
detection and monitoring of MRD in patients with MM and B-ALL using
DNA from bone marrow samples. In August 2020, clonoSEQ
received additional clearance from the FDA to detect and
monitor MRD in blood or bone marrow from patients with
CLL.
The clonoSEQ Assay leverages Adaptive’s proprietary immune
medicine platform to identify and quantify specific DNA sequences
found in malignant cells, allowing clinicians to assess and monitor
MRD during and after treatment. The assay provides standardized,
accurate and sensitive measurement of MRD that allows physicians to
predict patient outcomes, assess response to therapy over time,
monitor patients during remission and predict potential relapse.
Clinical practice guidelines in hematological malignancies
recognize that MRD status is a reliable indicator of clinical
outcomes and response to therapy, and clinical outcomes have been
shown to be strongly associated with MRD levels measured by the
clonoSEQ Assay in patients diagnosed with CLL, MM and
ALL.
The clonoSEQ Assay is a single-site test performed at Adaptive
Biotechnologies. In addition to its FDA-cleared uses, clonoSEQ
is also available as a CLIA-validated laboratory developed test
(LDT) service for use in other lymphoid cancers and sample types.
For important information about the FDA-cleared uses of clonoSEQ,
including the full intended use, limitations, and detailed
performance characteristics, please
visit www.clonoSEQ.com/technical-summary.
About AdaptiveAdaptive Biotechnologies is
a commercial-stage biotechnology company focused on harnessing the
inherent biology of the adaptive immune system to transform the
diagnosis and treatment of disease. We believe the adaptive immune
system is nature’s most finely tuned diagnostic and therapeutic for
most diseases, but the inability to decode it has prevented the
medical community from fully leveraging its capabilities. Our
proprietary immune medicine platform reveals and translates the
massive genetics of the adaptive immune system with scale,
precision and speed to develop products in our Immune Medicine and
Minimal Residual Disease (MRD) businesses. We have three commercial
products and a robust clinical pipeline to diagnose, monitor and
enable the treatment of diseases such as cancer, autoimmune
conditions and infectious diseases. For more information, please
visit adaptivebiotech.com and follow us
on www.twitter.com/adaptivebiotech.
Forward Looking StatementsThis press release
contains forward-looking statements that are based on management’s
beliefs and assumptions and on information currently available to
management. All statements contained in this release other than
statements of historical fact are forward-looking statements,
including statements regarding our ability to develop,
commercialize and achieve market acceptance of our current and
planned products and services, our research and development
efforts, and other matters regarding our business strategies, use
of capital, results of operations and financial position, and plans
and objectives for future operations.
In some cases, you can identify forward-looking statements by
the words “may,” “will,” “could,” “would,” “should,” “expect,”
“intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,”
“project,” “potential,” “continue,” “ongoing” or the negative of
these terms or other comparable terminology, although not all
forward-looking statements contain these words. These statements
involve risks, uncertainties and other factors that may cause
actual results, levels of activity, performance or achievements to
be materially different from the information expressed or implied
by these forward-looking statements. These risks, uncertainties and
other factors are described under "Risk Factors," "Management's
Discussion and Analysis of Financial Condition and Results of
Operations" and elsewhere in the documents we file with
the Securities and Exchange Commission from time to time.
We caution you that forward-looking statements are based on a
combination of facts and factors currently known by us and our
projections of the future, about which we cannot be certain. As a
result, the forward-looking statements may not prove to be
accurate. The forward-looking statements in this press release
represent our views as of the date hereof. We undertake no
obligation to update any forward-looking statements for any reason,
except as required by law.
MEDIA CONTACT:Laura
Cooper917-912-7195media@adaptivebiotech.com
ADAPTIVE INVESTORS:Karina
Calzadilla201-396-1687
Adaptive Biotechnologies (NASDAQ:ADPT)
Historical Stock Chart
From Apr 2024 to May 2024
Adaptive Biotechnologies (NASDAQ:ADPT)
Historical Stock Chart
From May 2023 to May 2024